TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03826641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1805
Description: Dapagliflozin/Metformin (Xigduo XR) 10/1000mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1805
Description: Dapagliflozin/Metformin (Xigduo XR) 10/1000mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1805
Description: Dapagliflozin/Metformin (Xigduo XR) 10/1000mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1805
Description: Dapagliflozin/Metformin (Xigduo XR) 10/1000mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1801
Description: Dapagliflozin/Metformin 10/1000mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1801
Description: Dapagliflozin/Metformin 10/1000mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1801
Description: Dapagliflozin/Metformin 10/1000mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1801
Description: Dapagliflozin/Metformin 10/1000mg
Study: NCT03570476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given orally

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Undergo surgery
Study: NCT04917666

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Horticultural therapy
Description: A structured 8-session group therapy program, in which participants learn about plants, green spaces, plant-human interactions. During the program, the participants are guided by therapist to grow or take care of both indoor and outdoor plants, do small horticulture projects (like cooking, making drinks, herb projects).

Intervention type: OTHER
Group type: OTHER
Intervention: Comparison
Description: 4 session of semi-structured and free engagement in activities of their choice. The activities that they could choose are mostly table-top activities which are solitary in nature, and does not require social interaction.
Study: NCT04076865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMLA (lidocaine) +Itch (Histamine and cowhage)
Description: Cutaneous anaesthesia: will be topically induced by using EMLA cream 5%, a local anaesthetic cream consisting of equal parts of lidocaine and prilocaine (1g contains 25 mg of lidocaine and 25 mg of prilocaine, AstraZeneca A/S, Albertslund, Denmark).~Histamine: To deliver histamine, standard allergy skin prick test (SPT) lancets are applied.~Cowhage: Cowhage spicules are 1-2 mm in length and have diameter of 1-3 um at their tip, once inserted into the epidermis, the spicules evoke a moderate sensation of itch and to a lesser extent sensations of burning and stinging pain.
Study: NCT03674645

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI acquisitions
Description: Procedure of the study is an MRI exam without any injection or invasive procedure, that will be performed on the Siemens Magnetom Aera imager of Liryc institute (L'Institut de RYthmologie et modélisation Cardiaque) (Xavier Arnozan site - Bordeaux)
Study: NCT02651311

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intermediate cervical plexus block
Description: ultrasound guided intermediate cervical plexus block with 0.25% ropivacaine 0.2 ml/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: fentanyl 0.5 µg/kg in postanesthetic care unit when more or equal to FLACC scale 4.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl
Description: fentanyl 0.5 µg/kg in postanesthetic care unit when more or equal to FLACC scale 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: ibuprofen in ward when more or equal to FLACC scale 4.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibuprofen
Description: ibuprofen in ward when more or equal to FLACC scale 4.
Study: NCT01143662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ypeginterferon alfa-2b
Description: sc, qw, for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ypeginterferon alfa-2b
Description: sc, qw, for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ypeginterferon alfa-2b
Description: sc, qw, for 48 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2a
Description: sc, qw, for 48 weeks.
Study: NCT03968263

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hycon device(Routine protocol)
Description: Hycon device will be activated half a turn every 3 days.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hycon device(Routine protocol)
Description: Hycon device will be activated half a turn every 3 days.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hycon device(Routine protocol)
Description: Hycon device will be activated half a turn every 3 days.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hycon device(Routine protocol)
Description: Hycon device will be activated half a turn every 3 days.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hycon device(Modified protocol)
Description: The activation period of the hycon device will be modified.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hycon device(Modified protocol)
Description: The activation period of the hycon device will be modified.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hycon device(Modified protocol)
Description: The activation period of the hycon device will be modified.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hycon device(Modified protocol)
Description: The activation period of the hycon device will be modified.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hycon device(Routine protocol) and Vibration(Acceledent)
Description: Hycon device will be activated half a turn every 3 days. Vibration will be applied 2 times 10 minutes per day.
Study: NCT00002704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Study: NCT01505608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Intravenous (IV) Irinotecan at a dose of 10mg/m2 on days 1-5 and 8-12 of each 28 day cycle.
Study: NCT03968263

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hycon device(Routine protocol) and Vibration(Acceledent)
Description: Hycon device will be activated half a turn every 3 days. Vibration will be applied 2 times 10 minutes per day.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hycon device(Routine protocol) and Vibration(Acceledent)
Description: Hycon device will be activated half a turn every 3 days. Vibration will be applied 2 times 10 minutes per day.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hycon device(Routine protocol) and Vibration(Acceledent)
Description: Hycon device will be activated half a turn every 3 days. Vibration will be applied 2 times 10 minutes per day.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hycon device(Modified protocol) and Vibration(Acceledent)
Description: The activation period of the hycon device will be modified. Vibration will be applied 2 times 10 minutes per day.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hycon device(Modified protocol) and Vibration(Acceledent)
Description: The activation period of the hycon device will be modified. Vibration will be applied 2 times 10 minutes per day.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hycon device(Modified protocol) and Vibration(Acceledent)
Description: The activation period of the hycon device will be modified. Vibration will be applied 2 times 10 minutes per day.
Study: NCT00002704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal cytarabine
Study: NCT03968263

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hycon device(Modified protocol) and Vibration(Acceledent)
Description: The activation period of the hycon device will be modified. Vibration will be applied 2 times 10 minutes per day.
Study: NCT01311440

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Atkins diet treatment
Description: Eat a diet containing 16 grams of carbohydrates per day, maximize on fat. Assure sufficient intake of micronutrients.
Study: NCT03882645

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHH-diet
Description: This study took the DASH Diet as the basic model and developed the Chinese Heart Healthy Diet ( CHH-diet) according to the principles in the 2016 Dietary Guidelines for Chinese Residents. The nutrients targets in CHH-diet are set as following: fat % of total kcal: 25-27% (saturated: 6%; monounsaturated: 12%; polyunsaturated: 8%); carbohydrate % of total kcal: 55-60%; protein % of total kcal: 17-19%; dietary fiber: 30 g/day; sodium: 3000 mg/day; potassium: 3700 mg/day; magnesium: 500 mg/day; calcium: 1200 mg/day. The total energy will be set according to how much participants are eating in run-in period.

Intervention type: OTHER
Group type: OTHER
Intervention: local usual diet
Description: The nutrients targets and total energy in usual diet are set according to how much participants are eating in run-in period.
Study: NCT04266236

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: L3 LPB
Description: ultrasound-guided L3 lumbar plexus block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: L3 LPB
Description: ultrasound-guided L3 lumbar plexus block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: L3 LPB
Description: ultrasound-guided L3 lumbar plexus block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: L4 LPB
Description: ultrasound-guided L4 lumbar plexus block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: T12 block
Description: ultrasound-guided thoracic 12th segment nerve block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: L3 QLB
Description: ultrasound-guided quadratus lumborum block at L3 level

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.375%ropivacaine 25 ml (Raropin)
Description: 0.375%ropivacaine (Raropin) 25ml will be given

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.375%ropivacaine 40 ml (Raropin)
Description: 0.375%ropivacaine (Raropin) 40ml will be given

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.375%ropivacaine 40 ml (Raropin)
Description: 0.375%ropivacaine (Raropin) 40ml will be given

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General anesthesia with tracheal intubation
Description: General anesthesia with tracheal intubation will be induced with sufentanil, propofol, vecuronium for every patient before the operation and maintained with sevoflurane during the operation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia with tracheal intubation
Description: General anesthesia with tracheal intubation will be induced with sufentanil, propofol, vecuronium for every patient before the operation and maintained with sevoflurane during the operation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia with tracheal intubation
Description: General anesthesia with tracheal intubation will be induced with sufentanil, propofol, vecuronium for every patient before the operation and maintained with sevoflurane during the operation
Study: NCT02607111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalteparin
Study: NCT01962272

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weekly nutritional counseling
Description: The counseling included assessment of food intake, advice about improvement, motivation and specific food plans, as well as motivation to comply to the recommended dose of Forticare®.
Study: NCT01180673

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MINT-TLC
Description: This intervention is based on established clinical practice guidelines for prevention and treatment of hypertension, which recommend weight loss (if overweight), limiting sodium and alcohol intake, regular physical activity, and eating a low-fat diet that is rich in fruit and vegetables. Seniors will attend weekly group classes conducted by trained research assistants for the first 12 weeks (intensive phase); followed by three individual motivational interview (MINT) sessions that will occur monthly over the next three months (extended phase); and finally each senior will receive three bi-monthly booster MINT sessions in the remaining six months (maintenance phase).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Condition
Description: Seniors randomized to the control arm will receive a single individual brief advice session on therapeutic lifestyle changes recommended for blood pressure reduction. In addition, they will be given print versions of the NHLBI publications Your Guide to Lowering Blood Pressure; and Facts about the DASH Eating Plan. Sessions will be delivered by trained research assistants.
Study: NCT04483713

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Workshop
Description: The workshop proposes a review of all stages of EBP which includes approaches to clinical care based on science and the quality of evidence, with the ultimate goal of promoting safe and quality care.~The workshops comprise one for each group with a total workload of six (6) hours divided into two days, lasting three hours each day. The first day will be a theoretical approach and the second day a practical approach.~The workshops with theoretical content and practical classes will be held in rooms of Albert Einstein Hospital.~All participants of both educational strategies will answer the same questionnaires.
Study: NCT03253328

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Arm N-acetyl cysteine (NAC)
Description: N-acetyl cysteine (NAC) 1200mg twice a day for 6 days post-amputation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Arm
Description: Placebo 1/2 normal saline infusion twice a day for 6 days post-amputation
Study: NCT02772627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebicapone
Description: Nebicapone 100 mg tablets; oral route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebicapone
Description: Nebicapone 100 mg tablets; oral route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebicapone
Description: Nebicapone 100 mg tablets; oral route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets; oral route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets; oral route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets; oral route.
Study: NCT01467830

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open Inguinal Hernia Repair With Mesh,the Use of Absorbable Versus Non Absorbable Fixation Sutures
Description: use of absorbable sutures to fixate mesh inguinal hernia repair.
Study: NCT00002704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Study: NCT01467830

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Open Inguinal Hernia Repair With Mesh,the Use of Absorbable Versus Non Absorbable Fixation Sutures
Description: use of absorbable sutures to fixate mesh inguinal hernia repair.
Study: NCT00317382

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound used to visualize spine to determine best location for lumbar puncture.
Study: NCT04937283

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Segmentectomy with systemic lymph node dissection
Description: Segmentectomy with hilar and mediastinal lymph node dissection is performed. If the tumor located at inter-segment plane and without sufficient resection margin distance, a combined segmentectomy will be performed. Systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed. At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively. The distance from the dissection margin to the tumor edge must be evaluated intra-operatively. If the distance is either less than the maximum tumor diameter or 20 mm, the absence of cancer cells in the resection margin must be histologically or cytologically confirmed before finishing surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lobectomy with hilar and mediastinal lymph node dissection
Description: Lobectomy with hilar and mediastinal lymph node dissection is performed. Segmentectomy with hilar and mediastinal lymph node dissection is performed. Systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed. At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively. The distance from the dissection margin to the tumor edge must be evaluated intra-operatively. If the distance is either less than the maximum tumor diameter or 20 mm, the absence of cancer cells in the resection margin must be histologically or cytologically confirmed before finishing surgery.
Study: NCT02929238

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polypropylene Suture Right Side
Description: Suture Description: The suture used in this study will be a sterilized polypropylene suture and individually crossed in the base of the wound. Polypropylene is commonly used for commercially available implanted meshes. The polypropylene suture is intended for single use only and the individual suture will be packaged and purchased sterile.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polypropylene Suture Left Side
Description: Suture Description: The suture used in this study will be a sterilized polypropylene suture and individually crossed in the base of the wound. Polypropylene is commonly used for commercially available implanted meshes. The polypropylene suture is intended for single use only and the individual suture will be packaged and purchased sterile.
Study: NCT01962272

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly nutritional counseling
Description: The counseling included assessment of food intake, advice about improvement, motivation and specific food plans, as well as motivation to comply to the recommended dose of Forticare®.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Forticare®.
Study: NCT03716661

Intervention type: PROCEDURE
Group type: OTHER
Intervention: ORIF
Description: Open Reduction Internal Fixation
Study: NCT02212769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan 50mg
Description: Losartan 50mg once daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan 50mg
Description: Losartan 50mg once daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1029M 1200mg and Losartan 50mg
Description: Losartan 50mg 1 Tablet once daily and DW1029M 300mg 2 Tablets b.i.d. for 7days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1029M 1200mg and Losartan 50mg
Description: Losartan 50mg 1 Tablet once daily and DW1029M 300mg 2 Tablets b.i.d. for 7days
Study: NCT02088567

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Total Knee Arthroplasty
Description: Total knee arthroplasty, per the usual practice of the physician.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Knee Arthroplasty
Description: Total knee arthroplasty, per the usual practice of the physician.
Study: NCT04483713

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Workshop
Description: The workshop proposes a review of all stages of EBP which includes approaches to clinical care based on science and the quality of evidence, with the ultimate goal of promoting safe and quality care.~The workshops comprise one for each group with a total workload of six (6) hours divided into two days, lasting three hours each day. The first day will be a theoretical approach and the second day a practical approach.~The workshops with theoretical content and practical classes will be held in rooms of Albert Einstein Hospital.~All participants of both educational strategies will answer the same questionnaires.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Workshop plus J. H. N. EBP Guide Tools
Description: In addition to the workshop. It will follow the same molds as the case of group Educational Workshop plus the Johns Hopkins Nursing Evidence-based Practice guide tools since the beginning of this practical class, when the participant will receive a description of a problem as a basis for elaborating their clinical question, and thus, move on to the next stage.~The tools will be offered in the case of this group: question development, evidence level and quality guide, research evidence assessment tool, individual evidence tool, evidence synthesis and recommendation tool, action planning tool and tool dissemination.
Study: NCT02981719

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: simultaneous gemcitabine and irreversible electroporation
Description: gemcitabine intravenous infusion prior to irreversible electroporation treatment
Study: NCT02765191

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plasma expansion with Ringer's Acetate
Description: 7,5 ml/kg mL Ringer's acetate during 5-10 minutes will be administered intravenously
Study: NCT02088567

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application of dHACM
Description: Application of dHACM at end of procedure before closing wound between the underlying fascia and the overlying skin layers to reduce scar formation
Study: NCT01089790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutogliptin
Description: 400 mg tablet, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: 100 mg capsule (each capsule contains two 50-mg tablets), once daily
Study: NCT03623009

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: An article meant to trigger certain psychosocial behaviors
Description: An article meant to trigger certain psychosocial behaviors is administered to the intervention arm prior to laparoscopic skills assessment.
Study: NCT03731065

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fructose-maltodextrin
Description: Fructose plus maltodextrin in a ratio of 1:1.4, diluted in water to produce a 16% carbohydrate solution.
Study: NCT03623009

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: a neutral article
Description: The control arm will receive a neutral article prior to completing the assessment.
Study: NCT02204488

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Joint Arthroplasty
Description: Total Joint Arthroplasty with device: Maïa® trapezio-metacarpal joint prosthesis, Groupe Lépine, Genay, France
Study: NCT02981719

Intervention type: PROCEDURE
Group type: OTHER
Intervention: irreversible electroporation
Description: percutaneous irreversible electroporation was performmed for locally advaanced pancreatic cancer.